INT111133

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 31
Total Number 31
Disease Relevance 10.89
Pain Relevance 8.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (Mapk3) mitochondrion (Mapk3) Golgi apparatus (Mapk3)
protein complex assembly (Mapk3) protein complex (Mapk3) cytoplasm (Mapk3)
Anatomy Link Frequency
cardiac myocytes 1
PSCs 1
brains 1
urothelial cells 1
hippocampus 1
Mapk3 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Morphine 21 100.00 Very High Very High Very High
Paracetamol 8 99.98 Very High Very High Very High
Pain 12 99.72 Very High Very High Very High
antagonist 3 99.50 Very High Very High Very High
Hippocampus 14 98.80 Very High Very High Very High
analgesia 7 98.36 Very High Very High Very High
opioid receptor 8 98.32 Very High Very High Very High
substance P 15 98.00 Very High Very High Very High
Inflammation 25 97.72 Very High Very High Very High
opiate 7 97.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hypoxia 14 100.00 Very High Very High Very High
Diabetes Mellitus 367 99.90 Very High Very High Very High
Injury 8 98.08 Very High Very High Very High
Nociception 18 97.76 Very High Very High Very High
Apoptosis 25 97.74 Very High Very High Very High
INFLAMMATION 31 97.72 Very High Very High Very High
Hyperalgesia 16 97.56 Very High Very High Very High
Pressure And Volume Under Development 2 95.88 Very High Very High Very High
Coronary Artery Disease 12 95.28 Very High Very High Very High
Urological Neuroanatomy 4 95.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Intracisternal pretreatment with PD98059, a p44/42 MAPK inhibitor, or SB203580, a p38 MAPK inhibitor, significantly reduced the decrease in the threshold of air puffs ipsilateral to the IL-1beta injection site produced by 10 pg of IL-1beta.
Negative_regulation (inhibitor) of p44
1) Confidence 0.57 Published 2005 Journal Neurosci. Lett. Section Abstract Doc Link 16084017 Disease Relevance 0.28 Pain Relevance 0.38
CONCLUSIONS: (1) Morphine inhibits hypoxia-induced VEGF transcription, in part, through an HIF-1alpha-mediated mechanism and (2) morphine inhibition of hypoxia-induced HIF-1alpha may be mediated by inhibition of ERK 1,2 MAP kinase activity and PI3 kinase activity.


Negative_regulation (inhibition) of ERK 1
2) Confidence 0.57 Published 2003 Journal Surgery Section Body Doc Link 12947338 Disease Relevance 0 Pain Relevance 0
TRPA1 was coexpressed with ERK1/2 in gastric primary afferent neurons, and attenuation of TRPA1 activation using antisense peptides and a specific blocker led to suppression of both ERK1/2 activation and visceromotor responses.
Negative_regulation (suppression) of ERK1 in afferent neurons
3) Confidence 0.57 Published 2010 Journal Digestion Section Abstract Doc Link 20588026 Disease Relevance 0.75 Pain Relevance 0.66
However, inhibition of ERK 1/2 and JNK had no effect on ethanoland acetaldehyde-induced alpha-SMA expression in PSCs.
Negative_regulation (inhibition) of ERK 1 in PSCs
4) Confidence 0.57 Published 2003 Journal Pancreas Section Body Doc Link 12883264 Disease Relevance 0 Pain Relevance 0
We examined the effect of intraplantar injection of an ERK1/2 inhibitor, PD98059, and a p38 inhibitor, SB202190, on BV-induced PSN, mechanical hyperalgesia, and inflammatory swelling.
Negative_regulation (inhibitor) of ERK1 associated with nociception, pressure and volume under development, hyperalgesia and inflammation
5) Confidence 0.42 Published 2009 Journal J Pain Section Abstract Doc Link 19038582 Disease Relevance 1.33 Pain Relevance 0.40
Specific inhibitors were also used to inhibit the activity of ERK 1/2 and JNK.
Negative_regulation (inhibit) of ERK 1
6) Confidence 0.42 Published 2003 Journal Pancreas Section Body Doc Link 12883264 Disease Relevance 0 Pain Relevance 0
The inhibitors of PLC, PKC, p38 MAPK, ERK1/2, and JNK caused long-lasting reductions of the mechanical hyperalgesia (inhibitions at 4 hrs of 100%, 90%, 97%, 90%, and 100%, respectively), but the PLA2 inhibitor reduced hyperalgesia only at 4 hrs (by 58%).
Negative_regulation (inhibitors) of ERK1 associated with hyperalgesia
7) Confidence 0.42 Published 2006 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 16741065 Disease Relevance 0.64 Pain Relevance 0.57
SB 203580 [a p38 mitogen-activated protein kinase (p38 MAPK) inhibitor] and PD 98059 (a p44/42 MAPK kinase inhibitor) were ineffective in modulating IL-1beta-induced SP synthesis and secretion, and p60c-src kinase activity in DRG neurons.
Negative_regulation (inhibitor) of p44 in DRG associated with substance p
8) Confidence 0.42 Published 2003 Journal Eur. J. Neurosci. Section Abstract Doc Link 14622206 Disease Relevance 0.05 Pain Relevance 0.48
Notably, pronounced downregulations of phosphorylated MEK (85%) and ERK1/2 (pERK1: 81%; pERK2: 80%) were quantitated in brains of opiate addicts.
Negative_regulation (downregulations) of ERK1 in brains associated with opiate
9) Confidence 0.42 Published 2004 Journal J. Neurochem. Section Abstract Doc Link 15198681 Disease Relevance 0.47 Pain Relevance 0.87
The non-competitive NMDA-receptor antagonist, MK-801, and a specific inhibitor of the ERK1/2 pathway, U0126, significantly attenuated the injury-elicited increases in Homer1a mRNA when compared to saline-treated animals.
Negative_regulation (inhibitor) of ERK1 associated with antagonist and injury
10) Confidence 0.42 Published 2006 Journal Neurosci. Lett. Section Abstract Doc Link 16448751 Disease Relevance 0.32 Pain Relevance 0.54
PD98059, a MEK1/2 inhibitor, abolished both ERK1/2 activation and infarct size limitation by DADLE.
Negative_regulation (abolished) of ERK1
11) Confidence 0.41 Published 2006 Journal Basic Res. Cardiol. Section Abstract Doc Link 16619106 Disease Relevance 0.33 Pain Relevance 0.44
Injection of SD-282, a selective p38 inhibitor, but not PD98059, an ERK1/2 inhibitor, attenuated the prostaglanin E2 release.
Neg (not) Negative_regulation (inhibitor) of ERK1
12) Confidence 0.41 Published 2005 Journal Neuropeptides Section Abstract Doc Link 16176831 Disease Relevance 0.13 Pain Relevance 0.71
The contraction was attenuated in a dose-dependent manner, by the PKC inhibitors bisindolylmaleimide I and calphostin C, the Rho-kinase inhibitor Y 27632, and the p44/42 MAPK inhibitor PD 098059.
Negative_regulation (inhibitor) of p44
13) Confidence 0.41 Published 2005 Journal Anesthesiology Section Body Doc Link 16129980 Disease Relevance 0 Pain Relevance 0
Inhibitors of protein kinase A, protein kinase G, p42 / p44-mitogen activated protein kinase and nitric oxide synthase also attenuated vincristine-induced hyperalgesia, but to a similar degree in both sexes.
Negative_regulation (Inhibitors) of p44 associated with vincristine and hyperalgesia
14) Confidence 0.41 Published 2003 Journal Neuroscience Section Abstract Doc Link 12809704 Disease Relevance 0.87 Pain Relevance 1.27
For example, SB203580 and PD 98059, in addition to inhibiting p38 and p44/42 MAPKs, have been shown to inhibit the activity of cyclooxygenases and thromboxane synthase [151].
Negative_regulation (inhibiting) of p44
15) Confidence 0.41 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2733095 Disease Relevance 0.20 Pain Relevance 0.03
These changes were accompanied by diminished superoxide levels, decrease in oxidatively modified proteins (-60.8%; p<0.05) and reduced p38-MAPK and ERK1/2 hyperactivation (-50.4% and -35.4%, respectively; p<0.05).
Negative_regulation (reduced) of ERK1
16) Confidence 0.41 Published 2009 Journal Diabetes Metab. Res. Rev. Section Body Doc Link 19177471 Disease Relevance 0 Pain Relevance 0
We found that N/OFQ, PDBu, and IDB increased the amount of phosphorylated ERK-1/2 and Elk-1; U0126, a specific inhibitor for ERK-1/2, attenuated the inhibitory effect of N/OFQ on the I(K).
Negative_regulation (inhibitor) of ERK-1
17) Confidence 0.30 Published 2010 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 20331962 Disease Relevance 0 Pain Relevance 0.23
At one day after STZ injection, retinal phosphor-p42/p44 MAP kinase levels were 7.43±0.93 pixels (n=5) in eyes receiving rAAV-lacZ, and was decreased to 4.58±1.36 pixels(n=5) in eyes receiving rAAV-angiostatin (Figure 8, p=0.043).
Negative_regulation (decreased) of p44 in eyes
18) Confidence 0.22 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2533034 Disease Relevance 0.36 Pain Relevance 0
Angiostatin specifically inhibits proliferation, induces apoptosis in vascular endothelial cells [12], and downregulates vascular endothelial growth factor (VEGF), the latter via inactivation of the p42/p44 MAP kinase pathway [9,13,14].
Negative_regulation (inactivation) of p44 in endothelial cells associated with apoptosis
19) Confidence 0.22 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2533034 Disease Relevance 1.01 Pain Relevance 0
We hypothesize that morphine inhibits myocardial VEGF expression by inhibiting hypoxia-induced factor 1alpha (HIF-1alpha) and the signal transduction mechanisms involving Erk-1,2 MAP kinase (p42/p44), and PI3 kinase activity (phospho-Akt).
Negative_regulation (inhibiting) of p44 associated with hypoxia and morphine
20) Confidence 0.18 Published 2003 Journal Surgery Section Abstract Doc Link 12947338 Disease Relevance 0.36 Pain Relevance 0.49

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox